Paroxysmal Extreme Pain Disorder Treatment
AssigneeConvergence Pharmaceuticals Limited
InventorValerie Morisset
Life of this patent
Estimating the term…
Abstract
The present invention is directed to the treatment of paroxysmal extreme pain disorder (PEPD) comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.
Claims9
1-12. (canceled)
A method for treating paroxysmal extreme pain disorder comprising administering to a subject in need thereof a therapeutically effective amount of compound (5R)-5-(4-{[(2-Fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof.
A method for treating paroxysmal extreme pain disorder comprising administering to a subject in need thereof a pharmaceutical composition comprising (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof.
A method of treating paroxysmal extreme pain disorder in a human subject wherein said method comprises:
- (a) detecting the presence of one or more genetic variations within the CACNA1A gene and/or the CACNA1B gene of said subject;
- and
- (b) administering (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof to said patient identified as having said one or more genetic variations.
A method for treating paroxysmal extreme pain disorder, wherein said method comprises the steps of:
- (a) obtaining a biological sample from a patient;
- (b) detecting the presence of one or more genetic variations within the CACNA1A gene and/or the CACNA1B gene of said subject, such that the presence of said one or more genetic variations is indicative that a paroxysmal extreme pain disorder patient will respond to treatment with (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof;
- and
- (c) administering (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof to said paroxysmal extreme pain disorder patient identified as having said one or more genetic variations.
A method of treating paroxysmal extreme pain disorder in a patient wherein said method comprises the steps of selecting a patient having one or more genetic variations within the CACNA1A gene and/or the CACNA1B gene followed by administering a therapeutically effective amount of (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide or a pharmaceutically acceptable salt thereof to said patient.
Dependencies are inferred from the claim text.